Coronary heart disease
Conditions
Interventions
40 mg group:before treatment, 5th, 15th, 20th, 30th, 60th, 90th and 120th days after treatment
20 mg group:before treatment, 5th, 15th, 20th, 30th, 60th, 90th and 120th days after treatment
Sponsors
Vasculocardiology Department, Liuzhou People's Hospital, Liuzhou, Guangxi
Eligibility
Sex/Gender
All
Age
34 Years to 82 Years
Inclusion criteria
Inclusion criteria: Diagnosed with coronary heart disease, never used statins of the crowd.
Exclusion criteria
Exclusion criteria: (1) The patient with persistent or elevated levels of transaminases; (2) The patient with severe creatine phosphokinase during the course of administration and accompanied by myositis and pancreatitis; (3) During the course of administration; (4) The patient with renal insufficiency caused by rhabdomyolysis; (5) The patient with atorvastatin calcium calcium allergy; (6) pregnant women and maternal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD34;CD133;KDR;C-X-C chemokine receptor type 4,CXCR4;vascular endothelial growth factor,VEGF;basic fibroblast growth factor , bFGF;Silent mating type information regulation 2 homolog- 1 Sirtuin type 1, Sirt1; | — |
Countries
China
Contacts
Public ContactJie Liu
Vasculocardiology Department, Liuzhou People's Hospital, Liuzhou, Guangxi
Outcome results
None listed